IL6 and obesity disorder: The model exhibits pronounced cardiometabolic dysfunction, including obesity, insulin resistance, dyslipidemia, QTc prolongation, reduced QRS amplitude, and elevated markers of myocardial injury (Troponin T, CK-MB) and systemic inflammation (IL-6, IL-1β, TNF-α) (p < 0.05).